# FDA Grants Aidoc Radiology AI Breakthrough Status > Source: [https://icharles.com/articles/aidoc-fda-breakthrough-radiology-ai](https://icharles.com/articles/aidoc-fda-breakthrough-radiology-ai) (canonical) > Author: iCharles News — iCharles, https://icharles.com > Published: 2026-06-26 ## TL;DR The FDA granted Aidoc's First Read tool Breakthrough Device Designation on June 25, 2026, making it the second generative AI radiology tool to receive that status this year. First Read drafts radiology reports by building on Aidoc's CARE foundation model. Aidoc supports diagnostic decisions across nearly 2,000 hospitals worldwide. Cognita, a Stanford researcher-founded startup acquired by Radiology Partners, received the first such designation in March 2026. ## What did the FDA just approve for Aidoc? The FDA granted Aidoc's **First Read** tool Breakthrough Device Designation on June 25, 2026. **First Read** is a generative AI tool that drafts radiology reports for radiologists to review. The designation applies specifically to four life-threatening findings that the tool can detect and describe. Aidoc [announced the designation](https://www.prnewswire.com/news-releases/aidoc-receives-fda-breakthrough-device-designation-for-ai-that-drafts-radiology-reports-302809910.html) via PR Newswire on the same day. ## Who is Aidoc? **Aidoc** is a clinical AI company that supports diagnostic decisions across nearly 2,000 hospitals worldwide. Its platform integrates into existing hospital IT infrastructure. First Read extends Aidoc's clinically validated **CARE™ foundation model** into report drafting workflows. ## How does First Read work? Traditional machine learning tools flag spots on an X-ray or CT scan for a radiologist to review and write up manually. First Read works differently. It processes the entire image and drafts many of its findings directly. A radiologist then reviews the draft. This approach is built on Aidoc's CARE™ foundation model and is designed to help radiologists meet rising imaging demand. ## Is Aidoc the only company to get this designation? No. As we read the reporting, two generative AI radiology tools have now received FDA Breakthrough Device Designation in 2026. [STAT News reported](https://www.statnews.com/2026/06/25/radiology-generative-ai-cognita-aidoc-fda-breakthrough-designation/) that **Cognita** received the first designation in March 2026. Aidoc's First Read received the second designation in June 2026. ## What is Cognita? **Cognita** is a generative AI radiology tool founded by Stanford researchers. It was acquired late last year by **Radiology Partners**, a large radiology practice. Its breakthrough designation came in March 2026, roughly three months before Aidoc's. ## How do the two designations compare? | Detail | Cognita | Aidoc First Read | |---|---|---| | Company | Cognita / Radiology Partners | Aidoc | | Founders | Stanford researchers | — | | Designation date | March 2026 | June 25, 2026 | | Scope reported | Chest X-ray interpretation, report drafting | Four life-threatening findings on chest X-rays | | Hospital reach | — | Nearly 2,000 hospitals | ## Why does this regulatory designation matter? The FDA's Breakthrough Device Designation is intended to speed up the review of devices that provide more effective treatment or diagnosis of serious conditions. Generative AI in radiology presents new challenges for traditional validation and regulatory frameworks, according to STAT News. Large vision language models can now process an entire image and draft findings — a capability that goes beyond older machine learning tools that only highlighted areas for human review. For builders tracking [Perplexity CEO hybrid AI](/articles/perplexity-ceo-hybrid-local-revenue) developments and similar AI infrastructure stories, the regulatory path for clinical generative AI is worth watching closely. ## What findings does First Read target? Aidoc's First Read received its breakthrough designation specifically for detecting and describing four life-threatening findings. The sources do not name all four findings individually. The tool is designed to help radiologists handle rising imaging demand by drafting report content for those critical cases. ## What is the CARE™ foundation model? The **CARE™ foundation model** is Aidoc's clinically validated AI model. First Read extends this model into report drafting workflows. Aidoc describes it as the foundation for its clinical AI solutions across hospital settings. --- **Key facts at a glance:** - Aidoc announced FDA Breakthrough Device Designation for First Read on **June 25, 2026** - First Read targets **four life-threatening findings** on chest X-rays - Aidoc operates across **nearly 2,000 hospitals** worldwide - **Cognita** (Radiology Partners) received the first generative AI radiology breakthrough designation in **March 2026** - Both tools use large vision language models to draft full radiology reports, not just flag findings --- The most confirmed next step from the sources is Aidoc's continued pursuit of FDA clearance for First Read, with the Breakthrough Device Designation now in place to support that process. ## Frequently asked questions **What is Aidoc's First Read tool?** **First Read** is a generative AI tool from Aidoc that drafts radiology reports for radiologists to review. It builds on Aidoc's clinically validated CARE™ foundation model. The FDA granted it Breakthrough Device Designation on June 25, 2026, specifically for detecting and describing four life-threatening findings on chest X-rays, helping radiologists manage rising imaging demand. **What does FDA Breakthrough Device Designation mean for a radiology AI tool?** The FDA's Breakthrough Device Designation is a pathway designed to speed up the review of devices that provide more effective diagnosis or treatment of serious conditions. For generative AI radiology tools like First Read and Cognita, it signals FDA engagement with a technology that challenges traditional validation and regulatory frameworks, according to STAT News reporting from June 25, 2026. **How is generative AI in radiology different from older AI tools?** Older machine learning systems analyzed images like X-rays and CT scans and highlighted specific spots for a radiologist to review and write up manually. Generative AI tools, using large vision language models, can process the entire image and draft many of the findings directly. A radiologist then reviews the AI-generated draft rather than writing the report from scratch. **What is Cognita and how does it relate to Aidoc's announcement?** **Cognita** is a generative AI radiology tool founded by Stanford researchers and acquired late last year by Radiology Partners, a large radiology practice. It received FDA Breakthrough Device Designation in March 2026. Aidoc's First Read received a separate designation in June 2026, making the two tools the first generative AI radiology products to earn this FDA status in 2026. **How many hospitals does Aidoc currently support?** Aidoc supports diagnostic decisions across nearly 2,000 hospitals worldwide, according to the company's announcement on June 25, 2026. Its platform is designed to integrate into a facility's existing IT infrastructure, enabling AI deployment at scale across radiology and other clinical workflows.